PatchMD, a leading innovator in transdermal nutrient delivery, is excited to announce the launch of its new GLP-1 Support ...

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

Despite the promising results, further research is needed before GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists ...

Health-care professionals, eager to support their patients diagnosed with diabetes or obesity, are writing more prescriptions ...

Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are ...

CordenPharma, a CDMO focused on peptides and peptide-based therapeutics, announced a partnership with Viking Therapeutics. The two companies will work together to ensure the production of Viking’s GLP ...

In recent years, the growing list of medical benefits for GIP and GLP-1 agonists (think Ozempic for diabetes or Zepbound for weight loss, among others) has caused demand to skyrocket ...

Use of GLP-1 receptor agonists for obesity was associated with a reduced risk of primary open-angle glaucoma (POAG) and ...

GLP-1 therapy is a groundbreaking approach in the treatment of obesity and metabolic health issues. GLP-1, or glucagon-like ...

LLY), maker of tirzepatide and dual GLP-1/GIP agonist treatment sold under Mounjaro and Zepbound name brands. As compounding ...